Key facts
- Tokiwa-Bio’s last known valuation is $1.5M (Nov 2017).
- It has raised $2.6M; the latest was Later Stage VC ($2.6M) in Oct 2025.
- Notable investors include Japan External Trade Organization, Kyoto University Innovation Capital, Joyo Capital Partners, Rohto Pharmaceutical, TOHOKU University Venture Partners.
- Status: Acquired/Merged (Operating Subsidiary).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Tokiwa-Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Tokiwa-Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tokiwa-Bio
Operator of a gene therapy company intended to explore the practical application of therapeutic drugs. The company uses artificially synthesized vectors to introduce multiple genes to the cytoplasm without damaging genes in the cell, enabling medical researchers to develop gene therapy drugs for rare diseases such as hemophilia and ischemic diseases.
- Sector
- Healthcare
- HQ
- Tsukuba, Japan
- Founded
- 2014
- Employees
- 12
- Website
- tokiwa-bio.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Tokiwa-Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tokiwa-Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tokiwa-Bio in its N-PORT filings yet. We sweep new filings monthly.